AzTrials
AzTrials

End Stage Renal Disease (ESRD)Phase 3EDENNCT01219959

Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in Diabetic Continuous Ambulatory Peritoneal Dialysis (CAPD) Patients

A Phase 3 study testing Dianeal and Dianeal, Extraneal, Nutrineal in people with End Stage Renal Disease (ESRD) and Diabetes, run by Vantive Health LLC at 16 sites in Colombia.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients leads to improved metabolic control as measured by the magnitude of change from the baseline… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
End Stage Renal Disease (ESRD), Diabetes, CAPD
What is being tested?
Dianeal and Dianeal, Extraneal, Nutrineal
Could I receive a placebo?
No, everyone receives an active treatment
How many people
71 participants
Where
16 sitesColombia
Study dates
Oct 2010to Jul 2011
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or Female patients 18 years of age or older
  • Diagnosis of ESRD [Glomerular Filtration Rate (GFR) ≤ 15 mL/min]
  • CAPD using only Dianeal, at least 1 exchange of 2.5% or 4.25% dextrose/day, no prescribed dry time
  • Diabetes Mellitus (Type 1 and 2)
  • HbA1c > 6.0% but ≤ 12.0%
  • Blood hemoglobin ≥ 8.0 g/dL, but ≤ 13.0 g/dL
  • Total Kt/V ≥ 1.7

Who cannot join

  • Blood Urea Nitrogen (BUN) > 95 mg/dL
  • Exposure to Extraneal within 60 days of Screening
  • Mean Arterial Pressure (MAP) ≥ 125 mm Hg, or volume depleted (MAP < 77mm Hg) at Screening
  • Peritonitis, exit-site or tunnel infection treated with antibiotics within last 30 days
  • Cardiovascular event within the last 30 days
  • Ongoing clinically significant congestive heart failure [New York Heart Association (NYHA) class III or IV]
  • Allergy to starch-based polymers, glycogen storage disease or isomaltose/maltose intolerance
  • Receiving rosiglitazone maleate

Trial locations and contacts

16 sites in 1 country.

16 sites in 1 country

Colombia16 sites
  • Nefrosalud Ltda

    Armenia

  • RTS Ltda Barranquila

    Barranquilla

  • RTS Ltda Soledad

    Bogotá

  • Rts Ltda Ag H.U.S

    Bucaramanga

  • RTS Ltda H.U.V

    Cali

  • RTS Ltda STR del Valle

    Cali

  • RTS Ltda Versalles

    Cali

  • Renal Therapy Services (RTS) Ltda Cartagena

    Cartagena

  • RTS Ltda Cucuta

    Cúcuta

  • RTS Ltda Girardot

    Girardot

  • Unidad Renal de Tolima

    Ibague

  • RTS Ltda Sucursal Medellin

    Medellín

  • RTS Ltda Valle de Aburra

    Medellín

  • RTS Ltda Sogamoso

    Sogamoso

  • RTS Sucrusal Tulua

    Tuluá

  • RTS Ltda Villavicencio

    Villavicencio

Other trials in Colombia

About this study

Official title: Multi-center, Prospective, Randomized Trial to Demonstrate Improved Metabolic Control of Dianeal, Extraneal, Nutrineal (D-E-N) Versus Dianeal Only in the Treatment of Diabetic CAPD Patients

Primary Objective: To demonstrate that use of glucose sparing prescriptions, Dianeal, Extraneal, Nutrineal (D-E-N) versus Dianeal only, in diabetic (Type 1 and Type 2) Continuous Ambulatory Peritoneal Dialysis (CAPD) patients leads to improved metabolic control as measured by the magnitude of change from the baseline value in the HbA1c levels.

Secondary Objectives: To demonstrate that use of glucose-sparing Peritoneal Dialysis solutions (D-E-N versus Dianeal only) in diabetic (Type 1 and Type 2) CAPD patients leads to lower glycemic-control medication requirements, decreased incidence of severe hypoglycemic events requiring medical intervention, improved metabolic control, nutritional status, and Quality of Life.

Being tested
Dianeal, Dianeal, Extraneal, Nutrineal
Keywords
ESRD, Diabetes, CAPD
Medical subject headings
Kidney Failure, Chronic, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • DianealDrug

    Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose

  • Dianeal, Extraneal, NutrinealDrug

    Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin

Study groups in NCT01219959
Study groupRoleWhat they receive
Non-glucose SparingActive comparatorDianeal only
Receives: Drug: Dianeal
Glucose SparingExperimentalDianeal, Extraneal, Nutrineal
Receives: Drug: Dianeal, Extraneal, Nutrineal

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change From the Baseline Value in HbA1c at Month 3 and 6

    HbA1c is a specific glycohemoglobin, and adduct of glucose attached to the beta-chain terminal valine residue. Measured using a Tina-quant immunological assay suitable for samples from end stage renal disease (ESRD) patients and with icodextrin metabolites or equivalent. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

Secondary outcomes (21)
  1. Change From Baseline in Glycemic Control Medication Usage at Month 3 and 6

    This data used diabetic prescription drug information from insulin and oral glycemic control concomitant medications reported. Glycemic control medications classes allowed were limited to insulin, sulfonylureas, and thiazolidinediones. Subjects were provided with a paper diary on which they recorded doses of all glycemic control medications taken for 1 day prior to the Screening visit and for 8 days prior to the study visits at Month 3 and Month 6. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  2. Number of Severe Hypoglycemic Event Requiring Medical Intervention

    Severe hypoglycemia is defined by DCCT (Diabetes Control and Complications Trial) as any episode requiring external assistance to aid recovery or resulted in seizures or coma and included, as part of the definition, that the subject's blood glucose concentration had to have been documented as < 50mg/dL (<2.8mmol/L) for hypoglycemia, and/or the clinical manifestations had to have been reversed with oral carbohydrate, intramuscular glucagon, or intravenous glucose. Descriptive statistics were done, no inferential statistical analyses were performed.

    Measured: Baseline through Month 6 (End of Study)

  3. Change From Baseline of Metabolic Control Determined by Lipid Profile and Triglycerides at Month 3 and 6

    Values for Total Cholesterol (TC), Low Density Lipoprotein Cholesterol (LDLC), High Density Lipoprotein Cholesterol (HDLC), Very Low Density Lipoprotein (VLDL), and Triglycerides are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  4. Change From Baseline of Metabolic Control Determined by Lipoproteins at Month 3 and 6

    Values for Lipoprotein A (Lp(a)), Apolipoprotein A1 (Apo A1), and Apolipoprotein B (Apo B) are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  5. Change From Baseline of Metabolic Control Determined by Insulin Action of Insulin and C-peptide at Month 3 and 6

    Values for Insulin and C-peptide are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  6. Change From Baseline of Metabolic Control Determined by Insulin Action of Pro-Insulin at Month 3 and 6

    Values for Pro-Insulin are provided. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  7. Number of Participants by Change From Baseline Score in Subjective Global Assessment (SGA) Class at Month 6

    Nutritional Status by SGA include the following: (a) Weight change over 6 months, (b) dietary history of food intake over the previous 24-hour period with a determination by the subject as to whether this was a typical or atypical diet for the subject, (c) significant and sustained gastrointestinal distress, (d) functional status, (e) metabolic stress including frequent infections, fever, peritonitis, uncontrolled diabetes and active inflammatory bowel disease. The SGA used a 7-point scale, where a decrease score in the change from baseline shows signs of increased malnourishment, and an increased score (e.g., +2) is improved nourishment. Scale: 6 - 7 = very mild risk to well-nourished; 3 - 5 = no clear sign of normal status or severe malnutrition; 1 - 2 = severely malnourished.

    Measured: Baseline and Month 6 (End of Study)

  8. Change From Baseline of Nutritional Status Determined by Albumin and Total Protein (Labs) at Month 3 and 6

    Values for Albumin and Total Protein are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  9. Change From Baseline of Nutritional Status Determined by PNA and nPNA (Labs) at Month 3 and 6

    Values for Protein Nitrogen Appearance (PNA) and normalized protein nitrogen appearance (nPRNA) are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  10. Change From Baseline of Nutritional Status Determined by Pre-albumin (Labs) at Month 3 and 6

    Values for Pre-albumin are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  11. Change From Baseline of Nutritional Status Determined by Drained Body Weight at Month 3 and 6

    Values for Drained Body Weight are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  12. Change From Baseline of Nutritional Status Determined by Body Mass Index (BMI) at Month 3 and 6

    Values for BMI are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  13. Change From Baseline of Nutritional Status Determined by Waist Circumference at Month 6

    Values for Waist Circumference are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 6 (End of Study)

  14. Change From Baseline of Nutritional Status Determined by Protein and Calories at Month 3 and 6

    Values for Protein and Calories are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  15. Change From Baseline in QOL Based pm the EQ 5D Questionnaire Index at Month 3 and 6

    European Quality of Life, 5 Dimensions (EQ-5D) generates a single index score based on a descriptive system that defines health in terms of 5 dimensions, consisting of mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The possible range for each dimension is 1 to 3, where 1=no problems, 2=moderate problems, 3=extreme problems. Higher score implies more problems (worsening). According to this classification, 243 potential health states are defined Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  16. Change From Baseline in QOL Based on the EQ 5D Quest Health Status at Month 3 and 6

    Visual analogue scale to generate a self-perceived rating of health status. Visual analogue scale is the second part of the questionnaire, asking to mark health status on the day of the interview on a 20 cm vertical scale with end points of 0 and 100. There are notes at the both ends of the scale that the bottom rate (0) corresponds to " the worst health you can imagine", and the highest rate (100) corresponds to "the best health you can imagine". Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  17. Change From Baseline in QOL Based on the Diabetes Symptom Checklist (DSC) at Month 3 and 6

    The Diabetes Symptoms Checklist was designed to assess the presence and perceived burden of diabetes-related symptoms. Respondents were to consider troublesomeness of 34 symptoms on a 5-point scale ranging from 5="extremely" to 1="not at all." For symptoms/side-effects not experienced, the item was scored as 0. Symptoms were grouped into the following subscales: psychological fatigue, psychological cognitive, neurology pain, neurology sensory, cardiology, ophthalmology, hypoglycemia, hyperglycemia. Subscale scores were calculated as the sum of the given subscale divided by the total number of items in the scale. Total score was computed from the sum of the 8 subscales and ranged from 0 to 40. Higher scores indicate greater symptom burden. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 3, Month 6 (End of Study)

  18. Change From Baseline of MRI Body Composition at Month 6

    Values for Abdominal Subcutaneous Fat Volume and Abdominal Visceral Fat Volume are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 6 (End of Study)

  19. Change From Baseline of Left Ventricular (LV) End Diastolic and Systolic Volume as Determined by MRI at Month 6

    Values for Left Ventricular (LV) End Diastolic and Systolic Volume are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 6 (End of Study)

  20. Change From Baseline of Left Ventricular (LV) Mass Without and With Pap Muscles as Determined by MRI at Month 6

    Values for Left Ventricular (LV) Mass Without and With Pap Muscles are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 6 (End of Study)

  21. Change From Baseline of Left Ventricular (LV) Ejection Fraction as Determined by MRI at Month 6

    Values for Left Ventricular (LV) Ejection Fraction are included. Statistical analysis includes estimates of Least Squares (LS) comparing differences between treatment groups by visit and p-value using analysis of covariance (ANOVA) testing that the differences=0.

    Measured: Baseline, Month 6 (End of Study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Oct 2010 (estimated)
  2. Study startOct 2010
  3. Primary completionJul 2011
  4. Study completionJul 2011

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
71 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01219959
Sponsor's protocol ID
51067
Acronym
EDEN
Status last verified
Jul 2025
First submitted
8 Oct 2010
Last updated
24 Jul 2025
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Dianeal and Dianeal, Extraneal, Nutrineal in people with End Stage Renal Disease (ESRD) and Diabetes, run by Vantive Health LLC at 16 sites in Colombia.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 24 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 16 sites in Colombia. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 3 Jun 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change From the Baseline Value in HbA1c at Month 3 and 6 (time frame: Baseline, Month 3, Month 6 (End of Study)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Jul 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in